1. Glycans of the immune system 1.1 Immune system 1.2 Glycans 1.3 Glycosylation 1.4 Glycan-binding proteins (GBPs) or lectins 2. C-type lectin in host-pathogen interactions 2.1 Structure 2.
2 C-type lectin receptors and infection biology 3. Galectins 3.1 Introduction 3.2 Role in infection 4. Siglecs and the immune system 4.1 Sialic acid recognition by siglecs and cis interactions with endogenous glycans 4.2 Sialoadhesin and cellular interactions in the immune system 5. CD22 and B cell signalling 6.
New CD33-related Siglecs in the innate immune system 7. Modulation of immune tolerance by Siglec-sialic acid interaction 8. Siglecs and immune regulation 8.1 Pathogen internalization by innate immune cells: phagocytosis and endocytosis by Siglec 9. Siglecs and the attenuation of inflammatory responses 9.1 Immune evasion by pathogens via Siglec ligation 9.2 Attenuation of DAMP-mediated inflammation by Siglecs 10. The regulation of the life span of myeloid cells in the context of inflammation by Siglec-8, Siglec-9, and Siglec-F 10.
1 Regulation of natural killer cell function by Siglec-7 11. Siglecs, dendritic cells, and T cell activation 11.1 Siglecs and the regulation of plasmacytoid dendritic cell function 11.2 Siglecs in conventional dendritic cells and the regulation of T cell activation and polarization 11.3 A direct role for Siglecs in T cells 11.4 Siglecs in B cell biology and the maintenance of immunological tolerance 12. Glycobiology of autoimmunity and chronic inflammation 13. Immune response and glycobiology 13.
1 Glycobiology of pathogens 13.2 Role of glycan-binding proteins 14. Glycobiology of fungus and infection 14.1 Pathogenic fungi 14.2 Candida albicans: glycans are central in host interactions 14.3 Aspergillus fumigatus 14.4 Cryptococcus neoformans and its capsule 14.5 Fungal glycans and drug targets 15.
Glycobiology of virus and infection 15.1 Zika virus 15.2 Coronavirus and COVID-19 15.3 Lassa 15.4 Mumps 15.5 Chlorella 15.6 Varicella zoster 15.7 Avian coronavirus 15.
8 Influenza A virus 15.9 Chikungunya virus 15.10 Semliki Forest virus 15.11 Herpes simplex virus (HSV) 15.12 Rabies virus 15.13 Rotavirus 15.14 Ross river virus 15.15 H1N1/H5N1 virus 15.
16 New Castle disease virus 16. Glycans as antibody epitopes 17. Glycobiology of bacteria and infection 17.1 Bacterial surface glycans as virulence factors 17.1.1 Polysaccharide capsules 17.1.2 Lipopolysaccharide (LPS) 17.
2 Mechanisms of colonization and invasion 17.2.1 Adhesins and receptors 17.2.2 Invasion factors 17.3 Bacterial toxins as glycosyltransferases 17.4 Glycan-based interaction of host and gut microflora: commensals and pathogens 18. Glycobiology of tumour and immunity 18.
1 Glycosylation in cancer 18.1.1 Altered branching and fucosylation of N-glycans 18.1.2 Increased mucins and truncated O-glycans 18.1.3 Increased and aberrant sialic acid expression 18.1.
4 Increased selectin ligand expression 18.2 Altered expression of blood groups 18.3 Altered expression of glycosphingolipids 18.4 Loss of GPI-anchor expression 18.5 Altered hyaluronan 18.6 Alterations in sulfated glycosaminoglycans 18.7 Altered cytoplasmic and nuclear O-GlcNAc 18.8 Mechanisms of altered glycan expression 18.
9 Glycan changes in cancer stem cells and during EMT 18.10 Clinical significance 19. Therapeutic strategies based on microorganism and virus protein-glycan interactions 19.1 Structure-function considerations of glycans 19.2 Pharmacological driving force: protein-GAG interactions and the glycan-protein network (GPN) 19.3 Identification of protein-specific GAG sequences 19.4 Therapeutic approaches.